Aviso: Este site agrega dados públicos oficiais da FDA, ClinicalTrials.gov, PubMed e SEC EDGAR apenas para referência geral. Não constitui aconselhamento médico, diagnóstico, recomendação de tratamento ou aconselhamento de investimento.

Ensaio clínico

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

NCT: NCT06472245 · RECRUITING

ID NCTNCT06472245
EstadoRECRUITING
Data de início2024-12-03
Conclusão2028-12-15
SponsorOSE Immunotherapeutics (INDUSTRY)
First posted
Last updated

Resumo breve

Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).

Fonte oficial

Ver no ClinicalTrials.gov →

Dados provenientes da API do ClinicalTrials.gov. Para consultar o estado mais recente, veja o registo oficial.

↑